A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

ClinicalTrials.gov ID: NCT05451849

Public ClinicalTrials.gov record NCT05451849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.

Study identification

NCT ID: NCT05451849
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: TCR2 Therapeutics; Industry
Enrollment: 14 participants

Conditions and interventions

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 21, 2022 (Actual)
Primary completion: Aug 30, 2025 (Actual)
Completion: Aug 30, 2025 (Actual)
Last update posted: Jul 13, 2026

2022 – 2025

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
University of California, San Francisco	San Franciso	California	94143	—
University of Miami	Miami	Florida	33146	—
National Cancer Institute	Bethesda	Maryland	20814	—
University of Minnesota, Masonic Cancer Center	Minneapolis	Minnesota	55455	—
Montefiore Einstein Cancer Center	The Bronx	New York	10461	—
University of Oklahoma	Oklahoma City	Oklahoma	73104	—
SCRI Oncology Partners	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05451849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 13, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05451849 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →